NCT03419325View on ClinicalTrials.gov

A Genomic Approach for Clopidogrel in Caribbean Hispanics

EARLY_PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

150

Participants

Timeline

Start Date

September 1, 2020

Primary Completion Date

April 30, 2023

Study Completion Date

December 30, 2024

Conditions
Cardiovascular Disease (CVD)StrokeAcute Coronary SyndromePeripheral Arterial DiseaseCoronary Artery DiseaseMyocardial Infarction
Interventions
GENETIC

CYP2C19 test

Patients will be categorized into 4 groups based on the results of their genetic test for CYP2C19 as well as the residual platelet reactivity test (P2RY12 assay=PRU units) and DAPT treatments options will be recommended accordingly (i.e., through a Clinical Decision Support (CDS) tool that is based on a pharmacogenetic-driven algorithm and the PRU result).

DIAGNOSTIC_TEST

P2RY12 assay

Patients will be categorized into 4 groups based on the results of their genetic test for CYP2C19 as well as the residual platelet reactivity test (P2RY12 assay=PRU units) and DAPT treatments options will be recommended accordingly (i.e., through a Clinical Decision Support (CDS) tool that is based on a pharmacogenetic-driven algorithm and the PRU result).

Trial Locations (2)

00984

University Hospital at Carolina, Carolina

00926

Cardiovascular Hospital of Puerto Rico and the Caribbean, San Juan

All Listed Sponsors
collaborator

National Institute on Minority Health and Health Disparities (NIMHD)

NIH

collaborator

Icahn School of Medicine at Mount Sinai

OTHER

lead

University of Puerto Rico

OTHER